Is TransMedics Group Stock a Buy?
TransMedics Group (NASDAQ: TMDX) has emerged as a medical devices industry leader, capturing strong growth and climbing profitability from its organ transplant delivery system. Since the company's 2019 initial public offering, the stock has returned a massive 285%.
That said, the early success hasn't been achieved without some stumbling blocks. The company's latest quarterly update came in below Wall Street estimates, and shares are down 49% from their 52-week high at the time of writing. The good news for TransMedics investors is that several factors still support a positive outlook, despite the volatility in the stock.
Is now the time to add TransMedics Group stock to your portfolio? Here's what you need to know.
Source Fool.com
